Detalhe da pesquisa
1.
A Phase II Study of Irinotecan for Patients with Previously Treated Small-Cell Lung Cancer.
Oncology
; 94(4): 223-232, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29444512
2.
A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016).
Invest New Drugs
; 35(2): 227-234, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28150074
3.
Critical Roles of Chemoresistant Effector and Regulatory T Cells in Antitumor Immunity after Lymphodepleting Chemotherapy.
J Immunol
; 195(2): 726-35, 2015 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26041539
4.
Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors.
BMC Cancer
; 16: 222, 2016 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26979596
5.
Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens.
Support Care Cancer
; 24(9): 4025-33, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27129842
6.
Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).
Jpn J Clin Oncol
; 45(7): 670-6, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25877748
7.
Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia.
Blood
; 120(12): 2417-27, 2012 Sep 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-22806892
8.
[A case of thymic cancer effectively treated by weekly paclitaxel combined with carboplatin].
Gan To Kagaku Ryoho
; 41(13): 2607-9, 2014 Dec.
Artigo
em Japonês
| MEDLINE | ID: mdl-25596057
9.
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
N Engl J Med
; 362(25): 2380-8, 2010 Jun 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-20573926
10.
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 3, X-linked is an immunogenic target of cancer stem cells.
Cancer Immunol Immunother
; 62(10): 1619-28, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23974721
11.
Eradication of established tumors in mice by a combination antibody-based therapy.
Nat Med
; 12(6): 693-8, 2006 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-16680149
12.
The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy.
Support Care Cancer
; 21(9): 2575-81, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23644992
13.
Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial.
Oncologist
; 17(6): 863-70, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22581822
14.
Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules.
J Immunol
; 184(10): 5493-501, 2010 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20400706
15.
A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy.
Support Care Cancer
; 20(7): 1507-14, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21808994
16.
Phase II study of nanoparticle albumin-bound paclitaxel monotherapy for relapsed non-small cell lung cancer with patient-reported outcomes (NLCTG1302).
Transl Lung Cancer Res
; 11(7): 1359-1368, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35958345
17.
Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501).
Cancers (Basel)
; 15(1)2022 Dec 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-36612200
18.
Vaccination with CD133(+) melanoma induces specific Th17 and Th1 cell-mediated antitumor reactivity against parental tumor.
Cancer Immunol Immunother
; 60(11): 1597-608, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21691723
19.
Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.
BMC Cancer
; 11: 1, 2011 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21194487
20.
A prospective phase II study of multimodal prophylactic treatment for afatinib-induced adverse events in advanced non-small cell lung cancer (Niigata Lung Cancer Treatment Group 1401).
Transl Lung Cancer Res
; 10(1): 252-260, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33569309